Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-27 @ 11:04 PM
Study NCT ID:
NCT04957160
Status:
COMPLETED
Last Update Posted:
2024-12-17
First Post:
2021-01-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
Sponsor:
Ipsen
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-09-09
Start Date Type:
ACTUAL
Primary Completion Date:
2022-06-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-06-15
Completion Date Type:
ACTUAL
First Submit Date:
2021-01-12
First Submit QC Date:
None
Study First Post Date:
2021-07-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-13
Last Update Post Date:
2024-12-17
Last Update Post Date Type:
ACTUAL